LUNA3: Rilzabrutinib for ITP
Description
In this episode of Don't Just Read the Abstract, Pip and Rich critically appraise LUNA3, a 2:1 randomised controlled trial of rilzabrutinib vs placebo in adults with persistent or chronic ITP. This is the first therapy to prove an improvement in fatigue in ITP, but does it live up to expectation? Listen to this episode and find out.
Do you like our show? Please share with friends, colleagues, and the wider world on social media.
References
HaemSTAR is an independent UK-wide network of registrars in clinical haematology, interested in promoting and performing research in classical haematology. Our focus is on collaborative projects across haemostasis & thrombosis, transfusion, general haematology, and obstetric haematology.
Hosted on Acast. See acast.com/privacy for more information.
United States
